NEW YORK, June 2 (GenomeWeb News) - Iconix Pharmaceuticals will provide chemogenomic profiling services for AstraZeneca, the company said today.
Under the agreement, Mountain View, Calif.-based Iconix will profile compounds from AstraZeneca for toxicity using its Drug Signatures library, a collection of predictive biomarkers derived from its chemogenomics reference database.